FEMPROX®, A TOPICAL ALPROSTADIL CREAM TREATMENT CONVEYS SUSTAINED IMPROVEMENT OF SEXUAL AROUSAL, LUBRICATION AND DESIRE IN WOMEN SUFFERING FROM FEMALE SEXUAL AROUSAL DISORDER (FSAD)

被引：0
|
作者：
Goldstein, I
Damaj, B. [1 ]
Fernando, Y. [1 ]
Frank, D. [1 ]
Moncada, I
机构：
[1] Apricus Biosci, San Diego, CA USA
来源：
JOURNAL OF SEXUAL MEDICINE | 2012年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：325 / 325
页数：1
相关论文
共 31 条
  • [21] Heart rate variability biofeedback increases sexual arousal among women with female sexual arousal disorder: Results from a randomized-controlled trial
    Stanton, Amelia M.
    Boyd, Ryan L.
    Fogarty, Justin J.
    Meston, Cindy M.
    BEHAVIOUR RESEARCH AND THERAPY, 2019, 115 : 90 - 102
  • [22] A Systematic Literature Review of Health-related Quality of Life Measures for Women with Hypoactive Sexual Desire Disorder and Female Sexual Interest/Arousal Disorder
    Lim-Watson, Michelle Z.
    Hays, Ron D.
    Kingsberg, Sheryl
    Kallich, Joel D.
    Murimi-Worstell, Irene B.
    SEXUAL MEDICINE REVIEWS, 2022, 10 (01) : 23 - 41
  • [23] Impact of age, race, and medication use on efficacy endpoints in a randomized controlled trial of topical sildenafil cream for the treatment of female sexual arousal disorder
    Johnson, Isabella
    Thurman, Andrea Ries
    Cornell, Katherine A.
    Dart, Clint
    Hatheway, Jessica
    Friend, David R.
    Goldstein, Andrew
    SEXUAL MEDICINE, 2024, 12 (05)
  • [24] A randomized, placebo-controlled, double-blind, parallel design study of the efficacy and safety of specially formulated alprostadil topical cream in patients with female sexual arousal disorder.
    Lao, QP
    Song, XH
    Geng, L
    Wang, XP
    Mo, J
    Lu, M
    FERTILITY AND STERILITY, 2005, 84 : S134 - S134
  • [25] The sensitivity of event logs, self-administered questionnaires and photoplethysmography to detect treatment-induced changes in female sexual arousal disorder (FSAD) diagnosis
    Rellini, A
    Meston, C
    JOURNAL OF SEXUAL MEDICINE, 2006, 3 (02): : 283 - 291
  • [26] MEASURES OF FEMALE SEXUAL DISTRESS IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL CREAM, 3.6% FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER
    Thurman, A.
    Cornell, K.
    Symonds, T.
    Dart, C.
    Hatheway, J.
    Friend, D.
    Goldstein, A.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [27] SEXUAL EXPERIENCES IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL, 3.6% CREAM FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER
    Thurman, A.
    Cornell, K.
    Symonds, T.
    Dart, C.
    Hatheway, J.
    Friend, D.
    Goldstein, A.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [28] Preliminary Efficacy of Sildenafil Cream, 3.6% in an Exploratory, Randomized, Placebo-Controlled, Phase 2b Trial for the Treatment of Female Sexual Arousal Disorder
    Thurman, A.
    Simon, J.
    Kingsberg, S. A.
    Cornell, K. A.
    Hatheway, J.
    Friend, D. R.
    Symonds, T.
    Goldstein, A.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [29] IMPACT OF ENROLLMENT DIAGNOSIS ON EFFICACY ENDPOINTS IN AN EXPLORATORY, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF SILDENAFIL CREAM, 3.6% FOR THE TREATMENT OF FEMALE SEXUAL AROUSAL DISORDER
    Thurman, A.
    Cornell, K.
    Symonds, T.
    Dart, C.
    Hatheway, J.
    Friend, D.
    Goldstein, A.
    JOURNAL OF SEXUAL MEDICINE, 2024, 21
  • [30] A Phase 2a Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial to Investigate the Efficacy, Safety, and Toleration of CP-866,087 (a High-Affinity Mu-Opioid Receptor Antagonist) in Premenopausal Women Diagnosed with Female Sexual Arousal Disorder (FSAD)
    Orri, Miguel
    Abraham, Lucy
    Giraldi, Annamaria
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 (10): : 2484 - 2496
1234